StockData

Aspira Women's Health Inc. (AWHL) stock

AWHLOTCIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 1/30
$0.22−0.01 (-2.61%)

Close on Oct 19, 2026Market cap $9.91MP/E –Yield –

Earnings

Aspira Women's Health's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q3 FY2025
$2.30M
0.0% on a year earlier
EPS, Q3 FY2025
–
Latest guidance
Raised
Nov 14, 2024 · 1 item

Quarterly results

Revenue and earnings per share from each of Aspira Women's Health's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2025ended Sep 30, 2025Nov 14, 2025before the open$2.30M0.0%–Release
Q2 FY2025ended Jun 30, 2025Aug 13, 2025after the close–––Release
Q1 FY2025ended Mar 31, 2025May 19, 2025before the open$2.28M+5.9%-$0.09Release
Q4 FY2024ended Dec 31, 2024Mar 27, 2025after the close$2.30M+9.5%-$0.08Release
Q3 FY2024ended Sep 30, 2024Nov 14, 2024before the open$2.30M––Release
Q2 FY2024ended Jun 30, 2024Aug 12, 2024after the close$2.42M–-$0.28Release
Q1 FY2024ended Mar 31, 2024May 15, 2024before the open$2.15M–-$0.39Release
Q4 FY2023ended Dec 31, 2023Mar 28, 2024after the close$2.10M–-$0.30Release
Q3 FY2023ended Sep 30, 2023Nov 13, 2023after the close–––Release
Q2 FY2023ended Jun 30, 2023Aug 14, 2023after the close–––Release
Q1 FY2023ended Mar 31, 2023May 11, 2023after the close–––Release
Q4 FY2022ended Dec 31, 2022Mar 22, 2023after the close–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Aspira Women's Health guided for has been reported

Guidance history

Every forecast Aspira Women's Health put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 14, 2024operating cash utilization targetFY2024$13.00M – $14.50MRaised
Aug 12, 2024operating cash utilization targetFY2024$13.00M – $14.50MLowered
Aug 12, 2024operating cash utilization targetFY2024$4.80M – $6.30MLowered
May 15, 2024operating cash utilization targetFY2024$15.00M – $18.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Aspira Women's Health filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. Results
  3. News
  4. Results
  5. News
  6. Results
  7. News
  8. Results
  9. News
  10. Update
  11. Results
  12. Update
  13. News
  14. News
  15. Update

See a number that looks wrong?